Human Genome Sciences raises $358M

Human Genome Sciences completed its stock offering Monday, raising $357.6 million through the sell of 26.7 million shares to the public (which paid $14 per share) and underwriters. The Rockville, MD-based developer beat its own expectations after setting out to gain $310 million from a sale of 21.5 million shares. After hovering around 45 cents per share through the spring, the company's stock now trades above $14 per share, thanks to unexpectedly positive late-stage data from its experimental lupus drug Benlysta. Release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.